Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Philogen SpA ( (IT:PHIL) ) has shared an update.
Philogen has continued to execute its share buyback programme on Euronext Milan, repurchasing 2,711 shares between 20 and 24 April 2026 at an average price of €20.9329, for a total outlay of €56,749.03. Since the programme’s launch, the company has acquired 68,849 shares for about €1.5 million, bringing its total treasury stock to 362,799 shares, or 0.8933% of its share capital, signalling ongoing capital management and confidence in its valuation.
The latest repurchases marginally increase Philogen’s treasury share position, which can be used over time to support corporate finance flexibility, potential incentive plans, or future strategic operations. While the percentage of capital involved remains small, the steady accumulation underscores management’s commitment to the buyback strategy as it advances its oncology-focused pipeline in a competitive biotech landscape.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR34.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology group focused on discovering and developing targeted anti-cancer drugs for diseases with high mortality rates. The company leverages proprietary tumour-targeting technologies, including antibody-based vascular targeting and DNA-Encoded Chemical Libraries, to selectively deliver potent therapeutics to tumour tissues while sparing healthy cells, with potential applications also in certain chronic inflammatory diseases.
YTD Price Performance: -11.16%
Average Trading Volume: 18,559
Technical Sentiment Signal: Hold
Current Market Cap: €605.3M
Find detailed analytics on PHIL stock on TipRanks’ Stock Analysis page.